OOIR: Observatory of International Research

Papers

(The H4-Index of Neurology-Neuroimmunology & Neuroinflammation is 45. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-03-01 to 2024-03-01.)

Article	Citations
Updated Diagnostic Criteria for Paraneoplastic Neurologic Syndromes	285
Guillain-Barré syndrome related to COVID-19 infection	267
Guillain-Barré syndrome: The first documented COVID-19–triggered autoimmune neurologic disease	183
Clinical approach to the diagnosis of autoimmune encephalitis in the pediatric patient	170
International multicenter examination of MOG antibody assays	161
COVID-19-related acute necrotizing encephalopathy with brain stem involvement in a patient with aplastic anemia	151
Acute disseminated encephalomyelitis after SARS-CoV-2 infection	150
COVID-19 outcomes in MS	127
Interleukin-6 in neuromyelitis optica spectrum disorder pathophysiology	111
Anti–SARS-CoV-2 antibodies in the CSF, blood-brain barrier dysfunction, and neurological outcome	101
Peripheral Neuropathy Evaluations of Patients With Prolonged Long COVID	100
COVID-19-associated acute necrotizing myelitis	99
Neurologic syndromes related to anti-GAD65	98
COVID-19 and MS disease-modifying therapies	84
Guillain-Barré syndrome related to SARS-CoV-2 infection	81
Acute Disseminated Encephalomyelitis and Acute Hemorrhagic Leukoencephalitis Following COVID-19	78
Neurosarcoidosis	76
Risk of COVID-19 infection in MS and neuromyelitis optica spectrum disorders	71
COVID-19 Among Patients With Multiple Sclerosis	66
BMI and low vitamin D are causal factors for multiple sclerosis	66
Clinical and imaging features of children with autoimmune encephalitis and MOG antibodies	65
Diagnostic yield of commercial immunodots to diagnose paraneoplastic neurologic syndromes	65
Ocrelizumab Extended Interval Dosing in Multiple Sclerosis in Times of COVID-19	64
Epidemiology of paraneoplastic neurologic syndromes and autoimmune encephalitides in France	64
Interleukin-6 Receptor Blockade in Treatment-Refractory MOG-IgG–Associated Disease and Neuromyelitis Optica Spectrum Disorders	63

International Consensus Recommendations for the Treatment of Pediatric NMDAR Antibody Encephalitis	63
Single-cell RNA-seq analysis of human CSF microglia and myeloid cells in neuroinflammation	63
COVID-19 infection in a patient with multiple sclerosis treated with fingolimod	60
Increased CSF levels of IL-1β, IL-6, and ACE in SARS-CoV-2–associated encephalitis	60
COVID-19-associated ophthalmoparesis and hypothalamic involvement	58
Overlapping central and peripheral nervous system syndromes in MOG antibody–associated disorders	57
Serum biomarkers in myelin oligodendrocyte glycoprotein antibody–associated disease	55
Rituximab, MS, and pregnancy	55
Rituximab Treatment and Long-term Outcome of Patients With Autoimmune Encephalitis	55
Monoclonal antibody treatment during pregnancy and/or lactation in women with MS or neuromyelitis optica spectrum disorder	53
COVID-19—White matter and globus pallidum lesions	53
COVID-19 Severity in Multiple Sclerosis	53
Clinical and MRI phenotypes of sarcoidosis-associated myelopathy	53
CNS inflammatory vasculopathy with antimyelin oligodendrocyte glycoprotein antibodies in COVID-19	51
Motor cortex transcriptome reveals microglial key events in amyotrophic lateral sclerosis	50
Presentations and mechanisms of CNS disorders related to COVID-19	49
Clinical spectrum and diagnostic pitfalls of neurologic syndromes with Ri antibodies	48
Clinical significance of Kelch-like protein 11 antibodies	48
Frequency of myelin oligodendrocyte glycoprotein antibody in multiple sclerosis	47
Dysregulation of the Adaptive Immune System in Patients With Early-Stage Parkinson Disease	45
Retinal Optical Coherence Tomography in Neuromyelitis Optica	45